Drug intelligence / Profile preview

biphasic insulin human

Development stage
Phase 4
Lead developer
Eli Lilly
Modality
Peptides
Administration
Subcutaneous
01

Overview

Humulin M30 (also known as Humulin M3 or Humulin 30/70) is a biphasic isophane human insulin suspension. It is a premixed formulation containing 30% soluble insulin (rapid-acting regular human insulin) and 70% isophane insulin (intermediate-acting NPH insulin). This combination provides dual-phase glucose control, where the soluble component rapidly manages postprandial blood glucose spikes and the isophane component provides sustained basal insulin coverage. Humulin M30 is administered subcutaneously and is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve glycemic control.

Brand names
Huminsulin 30/70Humulin 30/70Humulin M3Humulin M30Humulin Mixture 3Humulina 30/70Humuline 30/70Umuline Profil 30
Other names
biphasic insulin human 30/70biphasic isophane insulinbiphasic isophane insulin 30/70human insulin 30/70insulin human 30/70soluble insulin / isophane insulin 30/70
02

Targets

INSR (Insulin receptor)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on biphasic insulin human.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on biphasic insulin human.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call